MedPath

high lipid in blood and its management by garlic and tryoshnadi guggulu(Ayurvedic polyherbal formulation)

Phase 1/2
Not yet recruiting
Conditions
patients suffering from dyslipidemia
Registration Number
CTRI/2013/09/003952
Lead Sponsor
Institute for Post Gradute Teaching and Research of Ayurved Gujarat Ayurved Universuty jamnagar
Brief Summary

Dyslipidemia is elevation of plasma cholesterol, triglycerides (TGs), or both, or a low high-density lipoprotein level that contributes to the development of atherosclerosis. Causes may be primary (genetic) or secondary. Diagnosis is by measuring plasma levels of total cholesterol, TGs, and individual lipoproteins. Treatment is dietary changes, exercise, and lipid-lowering drugs.

There is no natural cutoff between normal and abnormal lipid levels because lipid measurements are continuous. A linear relation probably exists between lipid levels and cardiovascular risk, so many people with “normal†cholesterol levels benefit from achieving still lower levels. Consequently, there are no numeric definitions of dyslipidemia; the term is applied to lipid levels for which treatment has proven beneficial. Proof of benefit is strongest for lowering elevated low-density lipoprotein (LDL) levels. In the overall population, evidence is less strong for a benefit from lowering elevated TG and increasing low high-density lipoprotein (HDL) levels, in part because elevated TG and low HDL levels are more predictive of cardiovascular risk in women than in men.

HDL levels do not always predict cardiovascular risk. For example, high HDL levels caused by some genetic disorders may not protect against cardiovascular disorders, and low HDL levels caused by some genetic disorders may not increase the risk of cardiovascular disorders. Although HDL levels predict cardiovascular risk in the overall population, the increased risk may be caused by other factors, such as accompanying lipid and metabolic abnormalities, rather than the HDL level itself.

By seeing all conditions, we cannot find one to one co-relation with a single disease from *Ayurveda* classics, though condition is suggestive of pathologies like *Rasagata Ama, Raktagata Ama, Sthaulya, Medoroga, Medodosha* etc. By considering all the situations it can be assumed that of pathology is related to *Kapha Karaka Nidana* i.e.- *Santarpana Ahara Vihara*,which includes sedentary life style, high calories food intake, lack of exercise which finally leads to morbidity of *Kapha Dosha* and *Medo Dhatu.* Due to *Medodhatwagni Dusti* excessive accumulation of abnormal *Kapha*  and *Medo*  occurs in various *Strotas* in body. *Aparipakva Kapha – Meda* present in *Rasa-Raktavaha Strotasa* results in obstruction to the movement of *Vata & Rakta* through affected channel finally ends up in disease manifestation according to the site of affliction. The state of *Apakva Kapha* or *Meda* and its excessive presence *Margavarana* in *Rasa-Raktavaha* *Strotasa* is often compared with the state of dyslipidemia.

Hence, a formulation named *Tryoshnadiguggulu* containing *Ushna,Tikshna, Katu* and *Shrotoshodhaka* action was selected for patients of dyslipidemia, it may help to break the *Samprapti* or Clear the *Ama, Kapha*,and *Meda* and hence may help to manage the dyslipidemia.

Keeping in mind above facts, it may be said thatThe final purpose of management is to stop the formation of *Apakva Kapha* and *Meda* and to clear the *avarana* and then re-establishing the normal movement of *vata*.

Recent work on *Lasuna* has showed lipid/cholesterol lowering effect  and hence was also selected to establish its role in the management of dyslipidemia.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Patients having age between 25 – 60 years of either sex S.
  • Cholesterol > 200 mg/dlor/and S.
  • Triglyceride > 150 mg/dl or/and S.L.D.L >130 mg/dl or/and S.V.L.D.L>40 mg/dl or/and S.H.D.L <40 mg/dl.
Exclusion Criteria
  • •Age below 25 and above 60 years •Patients suffering from type 1 Diabetes mellitus and uncontrolled diabetes mellitus & uncontrolled hypertension •Drug induced & uncontrolled dyslipidemia •Systemic illness like Tuberculosis, Carcinoma and Endocrine disorders •Patient having the past history of M.I. & Unstable Angina.
  • •Patient having Clinical Features of CCF •Patient Having the major renal or liver disorder •Normal range of Apolipoprotien B is 40-125 mg/dl, if it increased with severity of symptoms, patients will be excluded.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Assessment will be made mainly based on the improvement observed in the subjective and objective parameters before treatment and after treatment. The prakriti, agnibala, roga bala and rogi bala will also be taken into considerationAssessment will be made mainly based on the improvement observed in the subjective and objective parameters before treatment and after treatment. The prakriti, agnibala, roga bala and rogi bala will also be taken into consideration
Secondary Outcome Measures
NameTimeMethod
assessment will be done by only symptoms.2 weeks

Trial Locations

Locations (1)

OPD no 21 Dept of Kayachikitsa Institute for Post Graduate Teaching and Research in Ayurveda

🇮🇳

Jamnagar, GUJARAT, India

OPD no 21 Dept of Kayachikitsa Institute for Post Graduate Teaching and Research in Ayurveda
🇮🇳Jamnagar, GUJARAT, India
Dr Bharat Padhar
Principal investigator
9638435942
dr.bharat1987@yahoo.in

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.